Phase 2 clinical study· 2015

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

Brines M|et al.

Molecular Medicine

PubMed: 25387363
Evidence level: moderate
Verification: verified

Summary

Exploratory study in people with type 2 diabetes and neuropathy.

Limitations

Small exploratory study|Multiple outcomes|No phase 3 confirmation

Linked peptides

ARA-290

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.